| Document |
Document Title |
|
WO/2019/154257A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
WO/2019/154247A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...
|
|
WO/2019/128154A1 |
Provided is a method for synthesizing the 17-position side chain of a steroid drug, wherein same is characterized in using compound I as a starting material, and the 17-position side chain is synthesized by nucleophilic, esterification, ...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/113494A1 |
Provided herein is a deuterated compound of Formula (I) Formula (I) or a pharmaceutically acceptable salt thereof, wherein R3a,R5, R6a, R6b, R17, R21a, R21b, Rm, Rn, R16a, R16 b, R7a, R7b, R12a, R12b, R11a R11b, R2a, R2b, R19, R4a, and R...
|
|
WO/2018/222701A1 |
The present application relates to methods of treating or preventing a renal disease, disorder, or condition (e.g., age-, diabetes- and/or obesity-related renal disease, disorder, or condition) in a subject in need thereof, comprising ad...
|
|
WO/2018/137260A1 |
Disclosed in the present application is a method for preparing a compound I, which is characterized in being prepared and obtained by reacting starting materials which comprise a compound II, which contains a carbon-carbon double bond, a...
|
|
WO/2018/127601A1 |
The present invention relates to aseptic suspensions, physically stable and injectable through a 25G needle or thinner, comprising crystalline, non- micronized 3-beta-hydroxy-5-alpha-pregnan-20-one particles, a mixture of acylglycerols a...
|
|
WO/2018/109508A1 |
The invention relates to the last step of a synthetic process, in which Nomegestrol- acetate of formula (I) is synthesized from 17α-acetoxy-6-methylene-19-norpregn-4-ene-3,20-dione of formula (II) in the presence of Pd/C catalyst and ac...
|
|
WO/2018/103626A1 |
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...
|
|
WO/2018/064649A1 |
Compounds are provided according to Formula (A): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1A, R1B, n, R2A, R2B, R3, and R4 are as defined herein. Compounds of the present invention ...
|
|
WO/2018/013615A1 |
Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b,R12, R16, R17, R19, and ----- are as define...
|
|
WO/2018/013613A1 |
Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a comp...
|
|
WO/2017/150723A1 |
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...
|
|
WO/2017/004205A1 |
The present invention relates to compounds and methods which may be useful as treatments of diseases.
|
|
WO/2016/209847A1 |
The present invention relates to C-20 steroid compounds, compositions and methods of use thereof to treat, minimize and/or prevent traumatic brain injury (TBI), including severe TBI, moderate TBI and mild TBI, including concussions.
|
|
WO/2016/164763A1 |
Described herein are deuterium-enriched neuroactive steroids of the Formula (II) or a pharmaceutically acceptable salt thereof; wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, Rlla, Rllb, R12a, R12b, R16a, R16b, R17, R19, Ra, and Rb and su...
|
|
WO/2016/154772A1 |
The present invention relates to a method for preparing 9β,10α-pregnane-4,6-diene-3,20-dione. The preparation method uses 9β,10α-pregnane-5,7-diene-3,20-dione diethyl diacetal (compound A) as a raw material, which is deprotected unde...
|
|
WO/2016/040322A1 |
Described herein are methods of treating tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from tremor, e.g., essential tremor;...
|
|
WO/2014/169833A9 |
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...
|
|
WO/2015/195962A1 |
Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment...
|
|
WO/2015/180679A1 |
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as def...
|
|
WO/2015/134670A1 |
In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to novel isotoplogues of 3α-hydroxy-3β-methyl-5α-pregnan-20-one (ganaxolone). In accordance with one a...
|
|
WO/2015/092647A1 |
The present invention relates to a new stereoselective process for the synthesis of 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(α)-17-acetyl-17-hy droxy-estr-4-e...
|
|
WO/2015/075693A1 |
The invention relates to a process for the synthesis of (11 β,17α)-17-acetoxy-11 - inethyl-19-norpregn-4-en-3,20-dione of formula (I) using the compound of formula (II) as starting material as well as the intermediates of the process.
|
|
WO/2015/049637A1 |
The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-m...
|
|
WO/2015/023593A1 |
This disclosure relates to progesterone phophate derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation such as those resulting from traumatic...
|
|
WO/2014/194068A1 |
Compounds which are glycosylates of an A-ring of a cardiotonic steroid, wherein the steroid is attached to the anomeric position of (a) a monosaccharide comprising a C-4 amino group, or (b) an oligosaccharide are provided.
|
|
WO/2014/169831A1 |
Provided herein are19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, ⃜⃜, R1, R2, R3a, R3b, R4a, and R 4bare as defined herein, and A is a carbon bound substituted or unsubstitu...
|
|
WO/2014/169836A1 |
Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditi...
|
|
WO/2014/100228A1 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorde...
|
|
WO/2014/083068A1 |
The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, Cl-8 alkyl, Cl-8 alkoxy, C2-C6 al...
|
|
WO/2014/067127A1 |
The present invention relates to a field of compound synthesis and specifically to novel method for the synthesis of 6-methyl-17α-acetoxy-19-norpregn-4,6-diene-3,20-dione. According to the method, norethisterone is used as the starting ...
|
|
WO/2014/058736A1 |
The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the tre...
|
|
WO/2013/092668A1 |
The invention relates to a process for ethynylating 16-methylene-17-keto steroids to the corresponding 16-methylene-17α-ethynyl-17β-hydroxy steroids by treatment with silyl-protected lithium acetylides followed by further desilylation....
|
|
WO/2013/056181A1 |
Provided herein are 3,3-disubstituted 19-nor- steroidal compounds according to Formula (I) and (III): where R1,R2, R3, R3', R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful fo...
|
|
WO/2013/009591A1 |
The invention relates to a novel crystallisation process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronisation. Said process comprises the step of dissolving flu...
|
|
WO/2012/160006A1 |
The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular dis...
|
|
WO/2012/159561A1 |
Provided is a preparation method for 17α-hydroxyprogesterone or analogs thereof, comprising the following steps: the compound as represented in formula (4) reacts in solvent and trihalomethane in the presence of magnesium metal and lith...
|
|
WO/2012/127176A1 |
The present invention relates to novel neurosteroids, especially derivatives of allopregnanolone and of epiallopregnanolone of formula (I) and the uses thereof as medicament for the treatment of neuropathologies, in particular neuropathi...
|
|
WO/2012/022880A2 |
The present invention relates to a method for synthesizing steroids, as well as to intermediate products and steroids produced by said method. In particular, the method of the present invention enables glycolsylated or non-glycosylated p...
|
|
WO/2012/011106A1 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2011/123911A1 |
The present invention can be used as an antitumoral medicament for testosterone-dependent tumours, in particular prostate cancer. The invention is a molecular compound formed by testosterone molecules chemically linked to molecules of a ...
|
|
WO/2011/073419A1 |
The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.
|
|
WO/2011/009530A2 |
The invention relates to 17-hydroxy-13-methyl-17-pentafluorethyl-11-acyloxyalkyleneph
enyl-dodecahydro-cyclopenta[a]phenanthrene-3-on derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the producti...
|
|
WO/2011/009534A2 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and...
|
|
WO/2011/009532A2 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethyinyl
phenyl derivatives of formula (I), wherein Y and X are defined as in the claims and in the description, to a method for the production thereof and to t...
|
|
WO/2011/009533A2 |
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethyinyl
phenyl derivatives of formula (I), wherein R1 and X are defined as in the claims and in the description, to a method for the production thereof and to ...
|
|
WO/2010/122096A1 |
The present invention relates to a process for obtaining compounds of formula (I) and (V), wherein R1 is C1-C6 alkyl; and R2 is OR3, OC(=O)R4 or O-(HPG), wherein R3 is H, C1-C6 alkyl or C6-C14 aryl; R4 is H or C1-C6 alkyl; and HPG is a h...
|
|
WO/2010/015528A1 |
The invention relates to compounds of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof (formula1) The compounds are useful for treating diabetic macular edema, diabetic retinopathy, macular degeneration,...
|
